JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300

Benzinga Newsdesk www.benzinga.com Positive 77.3%

Neg 0% Neu 0% Pos 77.3%

JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $300.